

2 April 2026

Emyria Launches NSW Workforce Campaign as National Expansion Accelerates

- **NSW recruitment campaign launched** – for psychiatrists and therapists – to establish Emyria’s fourth State-based clinical operation targeting Australia’s largest population
- **NSW mental health demand significant** – with psychological injury claims in the State having increased 64% since 2019-20, with NSW Police alone incurring ~\$1.75 billion in psychological injury costs over five years to June 2024^{1,2}.
- **Growing national clinical workforce** now exceeds 90 trained therapists across Western Australia, Queensland and Victoria, providing the foundation for interstate expansion into NSW.
- **Further domestic expansion mimics global momentum** in Psychedelic and next-generation mental health therapies

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce the commencement of a targeted clinical workforce recruitment campaign in New South Wales (NSW) to support the Company’s national growth strategy.

Clinical Workforce Recruitment in NSW to support National Growth Strategy

Emyria has commenced a targeted recruitment campaign for therapists and psychiatrists in Sydney, NSW, to support the establishment of Emyria’s fourth state-based clinical operation.

NSW represents Australia’s largest addressable patient population and is a strategic priority for the Company’s national expansion. The mental health burden in NSW is substantial: psychological injury claims in the state increased 64% between 2019-20 and 2023-24, with NSW Police alone incurring approximately \$1.75 billion in psychological injury compensation costs over the five years to June 2024^{1,2} – reflecting acute and growing demand for effective, evidence-based mental health interventions among frontline workers and the broader community.

Emyria’s targeted recruitment campaign is expected to accelerate the timeline to establishing a clinical presence in the state, building on a growing national workforce of more than 90 contracted and trained therapists across Western Australia, Queensland and Victoria.

Global momentum in Psychedelic mental health therapies

Global momentum in psychedelic and next-generation mental health therapies is accelerating toward a commercial inflection point, with multiple programs advancing into late-stage (Phase 3) trials, increasing regulatory alignment with significant strategic capital inflows, highlighted by Otsuka Pharmaceutical’s acquisition of Transcend Therapeutics for up to US\$1.225 billion³. This aligns Emyria’s clinical workforce, payer funded, national footprint scaling with rapidly emerging global interest as the sector transitions toward a transformative clinical inflection point.

Emyria’s Executive Chairman, Greg Hutchinson, said:

“The commencement of this targeted recruitment campaign in NSW reflects the accelerating pace of Emyria’s national expansion. NSW is Australia’s largest domestic market, and establishing a clinical presence in the state is an important step as we continue to broaden access to our services, scale our evidence-based care model and create meaningful long-term value for patients, clinicians and shareholders”.


Empax National Footprint & Growth

ASX: EMD | April 2026

EMPAX CENTRES

- Active Centres**
Perth, WA
Brisbane, QLD
Mornington Peninsula, VIC
- Next Expansion Target**
Sydney, NSW

National Reach
Emyria is expanding its Empax clinical network with therapist recruitment underway in **NSW**, building on established centres in three states.



Emyria Limited (ASX: EMD) | empaxcentre.com.au

Table 1 – Empax National Footprint and Next Growth Target

References:

1. https://www.sira.nsw.gov.au/__data/assets/pdf_file/0004/1336999/SIRA_Annual-Report-2023-24.pdf
2. <https://www.audit.nsw.gov.au/our-work/reports/the-mental-health-and-wellbeing-of-nsw-police>
3. <https://www.pharmaceutical-technology.com/news/otsuka-to-acquire-transcend-therapeutics/>

This release has been approved by the Board of Emyria

Greg Hutchinson | Executive Chairman

1300 436 363 | investors@emyria.com

For personal use only

emyria

Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development:

generates

Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression.

informs

Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria's unique therapy and drug development programs.

Emyria's Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.

EMYRIA'S INTERACTIVE INVESTOR HUB

[Investorhub.emyria.com](https://investorhub.emyria.com) Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.



CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown.

The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products' ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy.